Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.59 |
| ▸ | AGXT | P21549 | 2/20 | 0.59 |
| ▸ | MAOB | P27338 | 7/20 | 0.51 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | CMA1 | P23946 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1828440 | 0.81 | IDO1 (0.61) | IDO1AGXTMAOBTAAR1CHRM2 | |
| SCHEMBL5779495 | 0.78 | IDO1 (0.53) | IDO1AGXTMAOBTAAR1 | |
| SCHEMBL3768643 | 0.77 | IDO1 (0.71) | IDO1AGXTMAOBTAAR1CHRM2 | |
| SCHEMBL31264 | 0.77 | IDO1 (0.71) | IDO1AGXTMAOBTAAR1CHRM2 | |
| SCHEMBL5778928 | 0.77 | CYP3A4 (0.55) | IDO1AGXTMAOBTAAR1 | |
| SCHEMBL12093572 | 0.77 | IDO1 (0.65) | IDO1AGXTMAOBTAAR1CHRM2 | |
| SCHEMBL17218393 | 0.76 | IDO1 (0.54) | IDO1AGXTMAOBTAAR1CHRM2 | |
| SCHEMBL9945423 | 0.76 | IDO1 (0.54) | IDO1AGXTMAOBTAAR1CHRM2 | |
| SCHEMBL287942 | 0.75 | TSHR (0.48) | IDO1AGXTMAOB | |
| SCHEMBL29908907 | 0.75 | TAAR1 (0.62) | IDO1AGXTMAOBTAAR1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004089903-A9 | PIPERIDINE DERIVATIVES AS RENIN INHIBITORS FOR THE TREATMENT OF HYPERTENSION | WARNER LAMBERT CO (US) | 2005-10-27 | — | — | WO | disclosed |
| US-20040214832-A1 | Piperazine derivative renin inhibitors | WARNER-LAMBERT COMPANY LLC | 2004-10-28 | — | — | US | disclosed |
| WO-2004089915-A1 | PIPERAZINE DERIVATIVE RENIN INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-10-21 | — | — | WO | disclosed |
| US-20040204455-A1 | Piperidine derivative rennin inhibitors | WARNER-LAMBERT COMPANY LLC | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204455-A1 | Piperidine derivative rennin inhibitors | REN, ACE, HPN | IDO1 4079/4885AGXT 3314/4885MAOB 1068/4885 |
| US-20040214832-A1 | Piperazine derivative renin inhibitors | REN, ACE, AGTR2 | IDO1 4197/4885AGXT 1962/4885MAOB 1559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.